For more than 50 years, the NCI has supported a clinical trials infrastructure [the NCI National Clinical Trials Cooperative Group Program (CTCGP)] to conduct large-scale, clinical treatment trials across the nation. As part of its effort to take advantage of new discoveries in oncologic sciences, the NCI asked the Institute of Medicine (lOM) in 2009 to review the NCI-sponsored CTCGP. Based on the lOM review recommendations, as well as additional input received from stakeholders across the oncology community, the NCI has developed a comprehensive plan to transform the previous CTCGP that funded several separate organizations conducting cancer treatment trials into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The University of Pittsburgh Cancer Institute (UPCI) has been an NCI-designated Comprehensive Cancer Center since 1990. The UPCI has led ably and participated in several NCI CTCGPs, including ECOG, NSABP, RTOG, GOG, and ACOSOG. The UPCI now plans to participate under the new NCI NCTN as a Lead Academic Site. We propose to participate in NCTN as a Network Lead Academic Participating Site with the following Specific Aims: 1. To enhance the quality off scientific and administrative leadership in the development and conduct of clinical trials across the NCTN;2. To continue and improve our accrual to multi-center clinical trials at UPCI;To continue and improve processes for rapid activation of new trials at UPCI.

Public Health Relevance

As a Lead Academic Site of the NCI National Cancer Network, the UPCI intends to leverage its historical leadership in the cancer cooperative groups, as well as its sophisticated and vibrant clinical research programs, to reduce the burden of cancer through assistance in the conduct of large, multicenter, scientifically sound, important cancer clinical trials with the potential to change the standard of cancer care in the United States and worldwide.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Pili, Roberto; Jegede, Opeyemi; Carducci, Michael A et al. (2017) A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer 15:642-651.e1
Schneider, Bryan P; Shen, Fei; Gardner, Laura et al. (2017) Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clin Cancer Res 23:43-51
Marur, Shanthi; Li, Shuli; Cmelak, Anthony J et al. (2017) E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497
Bakhru, Pearl; Zhu, Meng-Lei; Wang, Hsing-Hui et al. (2017) Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2:
Kim, Kyu-Pyo; Parise, Robert A; Holleran, Julianne L et al. (2017) Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. J Pharm Biomed Anal 138:197-205
Kashani-Sabet, Mohammed; Nosrati, Mehdi; Miller 3rd, James R et al. (2017) Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res 23:6888-6892
Leng, Shuguang; Wu, Guodong; Klinge, Donna M et al. (2017) Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget 8:63978-63985
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697
Butterfield, Lisa H; Zhao, Fengmin; Lee, Sandra et al. (2017) Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res 23:5034-5043
Baggstrom, Maria Q; Socinski, Mark A; Wang, Xiaofei F et al. (2017) Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol 12:843-849

Showing the most recent 10 out of 38 publications